<DOC>
	<DOCNO>NCT00871117</DOCNO>
	<brief_summary>The purpose study evaluate immunogenicity safety Kinrix co-administered varicella ( Varivax® [ varicella virus vaccine live ] , Merck Company ) ( measles mumps rubella ) MMR vaccine , compare Kinrix co-administered MMR vaccine alone . Both Kinrix second dose Varivax indicate child 4-6 year age , great potential vaccine give concurrently . The aim trial demonstrate co-administered Varivax negatively affect immunogenicity reactogenicity Kinrix .</brief_summary>
	<brief_title>Immunogenicity Safety Kinrix + ( Measles Mumps Rubella ) MMR Vaccine With Without Varicella Vaccine Healthy Children 4-6 Years</brief_title>
	<detailed_description>Subjects 4-6 year age randomize two group receive either Kinrix , Varivax M-M-RII day 0 ( Group 1 ) Kinrix M-M-RII day 0 Varivax month 1 ( Group 2 ) . All subject group provide blood sample prior vaccination day 0 month 1 ( Group 2 , blood sample prior vaccination Varivax ) . Duration study approximately 6 month subject safety telephone contact 6 month vaccination .</detailed_description>
	<mesh_term>Diphtheria</mesh_term>
	<criteria>Subjects investigator believe parents/ guardian comply requirement protocol . A male female child 4 6 year age , inclusive . Written inform consent obtain parent guardian subject . Healthy subject establish medical history clinical examination enter study . Having receive 4 dos ( Diphtheria , Tetanus Acellular Pertussis ) DTaP vaccine use Pediarix and/or Infanrix , 3 dos poliovirus vaccine use Pediarix and/or ( inactivated poliovirus vaccine , Aventis Pasteur ) IPOL first 2 year life . Previously receive 1 dose MMRII Varivax ( separate combine ) second year life . Use investigational nonregistered drug vaccine study vaccine within 30 day precede administration study vaccine , plan use study period . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product device . History previous intercurrent diphtheria , tetanus , pertussis , polio , measles , mumps , rubella varicella disease , vaccination disease give second year life . Known exposure diphtheria , tetanus , pertussis , polio , prior vaccination . Poliovirus vaccination one dose ( oral polio virus ) OPV vaccine . Administration plan administration vaccine foreseen study protocol within 30 day study vaccination end Day 30 . Chronic administration plan administration immunosuppressant immune modify drug within six month prior study vaccination plan administration study period end Day 30 . Administration immunoglobulins and/or blood product time prior study vaccination plan administration study period end Day 30 . Any confirmed suspected immunosuppressive immunodeficient condition , include human immunodeficiency virus ( HIV ) infection . History seizures progressive neurological disorder , include infantile spasm , uncontrolled epilepsy progressive encephalopathy . Major congenital defect serious chronic illness . Acute disease time enrolment . History allergic disease reaction likely exacerbate component vaccine ( ) . History anaphylactic reaction egg proteins previous dos vaccine ( ) . Encephalopathy within 7 day administration previous dose Infanrix Pediarix . Fever &gt; =40.5°C 104.9°F ( rectal temperature ) ( 39.5°C 103.1°F , oral/axillary ) within 48 hour previous dose Infanrix Pediarix due another identifiable cause . Collapse shocklike state within 48 hour previous dose DTaP DTaPcontaining vaccine . Persistent , severe , inconsolable scream cry last ³3 hour occur within 48 hour administration previous dose DTaP DTaPcontaining vaccine . Thrombocytopenia follow previous dose MMRII component vaccine Inability contact parent/guardian subject telephone . Blood dyscrasia , leukemia , lymphomas malignant neoplasm affect bone marrow lymphatic system . Family history congenital hereditary immunodeficiency , unless immune competence subject demonstrate . Residence household follow person : Newborn infant ( 04 week age ) . Pregnant mother/women without documented positive history chickenpox disease laboratory evidence prior varicella vaccination . Pregnant woman beyond 28 week gestation regardless varicella vaccination status varicella disease history . Persons know immunodeficiency . Active untreated tuberculosis .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Co-administration</keyword>
	<keyword>Immunization</keyword>
	<keyword>Preschool</keyword>
	<keyword>Booster</keyword>
</DOC>